2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Neuroendocrine Tumors
6
Gastro-enteropancreatic neuroendocrine tumor
3
Neoplasms by Histologic Type
2
Neoplasms
2
Digestive System Neoplasms
2
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Oligometastatic Prostate Cancer (OMPC)
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
Lutetium-177
×
Clear all
NCT06531499
2025-12-31
RADIODOSE
Novartis
Phase 1
Recruiting
106 enrolled